Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-397-8 | CAS number: 1325-54-8 This substance is identified in the Colour Index by Colour Index Constitution Number, C.I. 40215.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
The acute toxicity of the substance has been determined in adequate studies in the rat following oral administration and in the rat and rabbit with dermal administrations. No studies are available for inhalation.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1993
- Reliability:
- 2 (reliable with restrictions)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Qualifier:
- according to guideline
- Guideline:
- other: WHO/VBC 88.953
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- other: TIf: RAI f (SPF)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: CIBA-GEIGY Limited Animal Production 4332 Stein / Switzerland
- Weight at study initiation: 177 to 206g
- Fasting period before study: overnight
- Housing: in Macrolon cages type 4, with standardized soft wood beeding.
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2 °C
- Humidity (%):55 ± 10%
- Air changes (per hr): 15 air changes per hour.
- Photoperiod (hrs dark / hrs light): 12 hour /day light cycle. - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- Administration of the test article: One single oral dose, by gastric intubation (gavage)
VEHICLE
Distilled water
- Concentration in vehicle: 10 ml/kg body weight
- Amount of vehicle (if gavage): 2000 mg/kg
- Lot/batch no. (if required): 623
- Purity: 27%
MAXIMUM DOSE VOLUME APPLIED: 2000 mg/kg
DOSAGE PREPARATION (if unusual):
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: - Doses:
- 2000 mg/kg (males and females)
Volume applied: 10 ml/kg bw - No. of animals per sex per dose:
- 5 males, 5 females (total number of animals: 10)
- Control animals:
- yes
- Details on study design:
- Limit test
Observations and records
Mortality: daily; a.m. and p.m. on working days, a.m. on weekend days.
Signs and symptoms; daily for 14 days.
Body weight: immediately before administration and on days 7 and 14.
Necropsies: The animals were submitted to a gross necropsy at the end of the observation period. - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortalities occurred in this study.
- Clinical signs:
- other: Piloerection, hunched posture, and dyspnea were seen, being common symptoms in acute tests . Additionally, diarrhea was observed in the females. The animals recovered within 5 days.
- Gross pathology:
- At necropsy, a spotted thymus was found in one female. No deviations from normal morphology were found in the remaining animals.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Upon an acute oral administration and a 14 day post-treatment observation period, the following LD50 (with 95% confidence limits calculated , where possible) was determined for the tested material.
LD50 in male rats: greater than 2000 mg/kg body weight
LD50 in female rats: greater than 2000 mg/kg body weight
LD50 in rats of both sexes: greater than 2000 mg/kg body weight - Executive summary:
10 young adult rats (5 males and 5 females Tif: Rai f) were housed in Macrolon cages type 4 and acclimatized at least for 5 days before administration. 2000 mg/kg of the test article solved in water was administrated in one single oral dose by gastric intubation. During 14 days the mortality, signs and symptoms were observed daily. The body weight was measured immediately before administration and on days 7 and 14 of the study and necropsies at the end of the observation period.
In conclusion, after 14 day post-treatment observation period, the LD50 in rats of both sexes is greater than 2000 mg/kg body weight.
Reference
|
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Three studies available, one of them according to GLP standards (key study). The two supporting studies are not performed following GLP.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Five male and five female Wistar (RccHanÔ:WIST) strain rats were supplied by Harlan Laboratories UK Ltd., Oxon, UK. On receipt the animals were randomly allocated to cages.
The females were nulliparous and non-pregnant. After an acclimatization period of at least five days the animals were selected at random and given a number unique within the study by indelible ink-marking on the tail and a number written on a cage card. At the start of the study the animals weighed at least 200 g, and were eight to twelve weeks of age. The weight variation did not exceed ±20% of the mean weight for each sex.
The animals were housed in suspended solid floor polypropylene cages furnished with woodflakes. The animals were housed individually during the 24-Hour exposure period and in groups of five, by sex, for the remainder of the study. Free access to mains drinking water and food (2014C Teklad Global Rodent diet supplied by Harlan Laboratories UK Ltd., Oxon, UK) was allowed throughout the study. The diet, drinking water and bedding were routinely analyzed and were considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study.
The temperature and relative humidity were set to achieve limits of 19 to 25 °C and 30 to 70% respectively. Any occasional deviations from these targets were considered not to have affected the purpose or integrity of the study. The rate of air exchange was at least fifteen changes per hour and the lighting was controlled by a time switch to give twelve hours continuous light (06:00-18:00) and twelve hours darkness.
The animals were provided with environmental enrichment items which were considered not to contain any contaminant of a level that might have affected the purpose or integrity of the study. - Type of coverage:
- semiocclusive
- Vehicle:
- water
- Duration of exposure:
- 24-hour contact period
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- five (5) male and five (5) female
- Details on study design:
- On the day before treatment the back and flanks of each animal were clipped free of hair.
Using available information on the toxicity of the test item, a group of five male and five female rats was treated with the test item at a dose level of 2000 mg/kg.
The appropriate amount of test item, moistened with distilled water, was applied as evenly as possible to an area of shorn skin (approximately 10% of the total body surface area). A piece of surgical gauze was placed over the treatment area and semi occluded with a piece of self adhesive bandage. The animals were caged individually for the 24-Hour exposure period.
Shortly after dosing the dressings were examined to ensure that they were securely in place.
After the 24-Hour contact period the bandage was carefully removed and the treated skin and surrounding hair wiped with cotton wool moistened with distilled water to remove any residual test item. The animals were returned to group housing for the remainder of the study period.
The animals were observed for deaths or overt signs of toxicity ½, 1, 2 and 4 hours after dosing and subsequently once daily for fourteen days.
After removal of the dressings and subsequently once daily for fourteen days, the test sites were examined for evidence of primary irritation and scored according to the scale from Draize J H (1977) "Dermal and Eye Toxicity Tests" In: Principles and Procedures for Evaluating the Toxicity of Household Substances, National Academy of Sciences, Washington DC p.31.
Any other skin reactions, if present were also recorded.
Individual body weights were recorded prior to application of the test item on Day 0 and on Days 7 and 14.
At the end of the study the animals were killed by cervical dislocation. All animals were subjected to gross necropsy. This consisted of an external examination and opening of the abdominal and thoracic cavities. The appearance of any macroscopic abnormalities was recorded. No tissues were retained. - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- There were no deaths
- Clinical signs:
- other: No signs of systemic toxicity were noted during the observation period.
- Gross pathology:
- No abnormalities were noted at necropsy
- Other findings:
- Orange coloured staining, not preventing evaluation of skin responses, was noted at the test sites of all animals during the study.
Physical damage caused on bandage removal was noted at the test site of one male 1 to 10 days after dosing. Small superficial scattered scabs and glossy skin were also noted at this test site 11 and 12 days after dosing with glossy skin persisting 13 and 14 days after dosing.
There were no signs of dermal irritation noted at the test sites of the remaining nine animals. - Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The acute dermal median lethal dose (LD50) of the test item in the Wistar strain rat was found to be greater than 2000 mg/kg body weight
- Executive summary:
A group of ten animals (five males and five females) was given a single, 24 hour, semi-occluded dermal application of the test item to intact skin at a dose level of 2000 mg/kg bodyweight. Clinical signs and body weight development were monitored during the study. All animals were subjected to gross necropsy (No abnormalities were noted at necropsy).
The observation on mortality showed that there were no deaths. Clinical observations showed no signs of systemic toxicity. Observation on dermal irritation showed a physical damage caused on bandage removal, small superficial scattered scabs and glossy skin were confined to the test site of one male. There were no signs of dermal irritation noted at the test sites of the remaining nine animals. Observations in body weight gave as a result that one female showed expected gain in bodyweight during the first week but body weight loss during the second week. Two females showed bodyweight loss or no gain in body weight during the first week with expected gain in bodyweight during the second week. Remaining animals showed expected gains in body weight during the study.
Reference
Individual Dermal Reactions - Males
Dose level mg/kg | Animal number and sex | Observation | Effects noted after initation of exposure (days) | |||||||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |||
2000 | 1 -0 male | Erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Other | STAPd | STAPd | STAPd | STAPd | STAPd | Pd | Pd | Pd | Pd | Pd | SsG | SsG | G | G | ||
1 -1 male | erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
other | STA | STA | STA | STA | STA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
1 -2 male | erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
other | STA | STA | STA | STA | STA | STA | STA | STA | 0 | 0 | 0 | 0 | 0 | 0 | ||
1 -3 male | erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
other | STA | STA | STA | STA | STA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
1 -4 male | erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
other | STA | STA | STA | STA | STA | STA | STA | STA | STA | 0 | 0 | 0 | 0 | 0 |
Individual Dermal reactions - females
0: no reactions; STA: Orange coloured staining; Pd: Physical damage caused on bandage removal; Ss: Small superficial scattered scabs; G: Glossy skin.
Individual Dermal reactions - females
Dose level mg/kg | animal number and sex | observation | Effects noted after initiation of exposure (days) | |||||||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |||
2 -0 female | erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
other | STA | STA | STA | STA | STA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
2 -1 female | erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
other | STA | STA | STA | STA | STA | STA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
2 -2 female | erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
other | STA | STA | STA | STA | STA | STA | STA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
2 -3 female | erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
other | STA | STA | STA | STA | STA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
2 -4 female | erythema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
other | STA | STA | STA | STA | STA | STA | STA | STA | 0 | 0 | 0 | 0 | 0 | 0 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Two studies available, one of them according to GLP standards (key study). The supporting study confirms the result found and used for assessment.
Additional information
Acute oral toxicity:
Two oral acute toxicity studies are available for CAS 1325-54-8 / EC 215-397-8. One of them is a limit test done according to OECD Guideline 401, Hartmann HR (1993), where rats were administered orally (gavage) 0 and 2000 mg/kg bw. No remarcable clinical signs were observed (male/female), no deaths occured and no remarkable macroscopic changes were observed in both male/female. With this study a LD50 > 2000 mg/kg bw was determined.
In an older test from Thomann P (1973) the rats were feeded with different doses of substance from 1000 to 10.000 mg/kg and a LD50 of 8700 mg/kg was obtained by calculation of probit analysis.
In addition one study performed with CAS 1195028-55-7 and following test method EU method B.1, Alvarez i Genoher N (2003), gave a result of LD50 > 2500 mg/kg bw. This substance has an identical structure to CAS 1325-54-8 in respect of the anionic components . It is considered that both substances have the same mode of action.
The study of Hartmann HR (1993) has been chosen as key study.
Acute inhalation toxicity:
There isn't any test available for acute inhalation toxicity. The exposure of humans via inhalation is unlikely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size.
Acute dermal toxicity:
Two studies of dermal toxicity of CAS 1325-54-8 / EC 215-397-8 are available. One of the studies Morena M (1980), was done following the guidances of 16 CFR Part 1500 - HAZARDOUS SUBSTANCES AND ARTICLES; ADMINISTRATION AND ENFORCEMENT REGULATIONS. The substance was applied dissolved into the skin of rabbit and observations were done on toxicity and mortality. An LD50 >2000 mg/kg bw was determined.
The other study of Pooles A (2013) followed OECD Guideline 402 and EU Method B.2. In this study the substance was applied to the skin of Wistar rat at a limit dose of 2000 mg/kg bw. Erythema and edema were monitored and scored. No deaths occured during or/and after the observation period and no signs of systemic toxicity were observed. Also no abnormalities were found at necropsy. As a remark, and as consquence of the nature of the substance, an orange coloured staining was seen in the site of application, but this effect didn't prevent to evaluate the skin responses. With this study an LD50 > 2000 mg/kg bw has been determined.
The study of Pooles A (2013) has been chosen as key study.
Justification for selection of acute toxicity – oral endpoint
The study is a GLP compliant and has Klimisch score 2.
Justification for selection of acute toxicity – dermal endpoint
The study is a GLP compliant and has Klimisch score 1
Justification for classification or non-classification
Acute oral toxicity
Based on the results of acute oral toxicity testing, CAS 1325-54-8 / EC 215-397-8 is not classified as "Harmful if swallowed" according to the EU DSD classification criteria (EU Directive 67/548/EEC). According to the EU CLP classification criteria (EU Regulation 1272/2008),CAS 1325-54-8 / EC 215-397-8 is not classified as hazardous.
The criteria in CLP Regulation establishes the limit for classification as Acute Tox Oral Category 4 in 2000 mg/kg, and the value obtained is >2000 mg/kg bw.
Acute inhalation toxicity
There isn't any test available for acute inhalation toxicity. The exposure of humans via inhalation is unlikely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size.
Acute dermal toxicity
Based on the results of acute dermal toxicity testing CAS 1325-54-8 / EC 215-397-8 is not classified as harmful for skin according to the EU DSD classification criteria (EU Directive 67/548/EEC). According to the EU CLP classification criteria (EU Regulation 1272/2008),CAS 1325-54-8 / EC 215-397-8 is not classified as hazardous for this hazard class.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
